NCT06959082View on ClinicalTrials.gov

Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions

Head and Neck Cancer Squamous Cell Carcinoma

Interventions

DRUG

VS-101

VS-101

DRUG

Cisplatin

Cisplatin

RADIATION

Radiation

Radiation

All Listed Sponsors

lead

VSPharmTech Co.,Ltd.

INDUSTRY